You are here: Home ยป Archives for healthcare

Advanced Care Group Expands Healthcare Personnel Recruitment Services into UAE and Saudi Arabia

DUBAI, United Arab Emirates, Oct. 14, 2024 (GLOBE NEWSWIRE) — Advanced Care Group (AC Group), a leader in healthcare recruitment, is thrilled to announce its expansion into the United Arab Emirates and Saudi Arabia, with new headquarters in Dubai and a regional office in Riyadh. This strategic move positions AC Group to address the growing demand for skilled healthcare professionals in two of the Middle East’s most dynamic markets.

With extensive experience and deep knowledge in working with hospital leadership, AC Group specializes in recruiting and placing hospital executives and nurse managers. Additionally, we leverage our global talent pools to source frontline personnel, ensuring that healthcare facilities have access to highly qualified floor staff when needed.

“We’re excited to bring our expertise to the UAE and Saudi Arabia, helping healthcare organizations access the best talent from around the globe,” said Kris Stewart, Founder & CEO of AC Group. “This expansion represents a significant milestone for us, as we work to build strong local partnerships and deliver the high–quality recruitment solutions that healthcare providers need.”

Stewart will be showcasing AC Group’s offerings at the Global Health Exhibition in Riyadh from October 21 to 23, 2024, at booth H1C V95. This exhibition marks a key moment for AC Group’s expansion in the region, offering a unique opportunity to engage directly with healthcare leaders and stakeholders. The company is also preparing for Arab Health in Dubai, scheduled for January 2025, where it will continue to showcase its capabilities and commitment to advancing healthcare across the region.

For more information about AC Group’s services or to connect with us at these events, contact:

Kris Stewart
Founder & CEO
AC Group
Tel: +971–800–03111–256
Email: [email protected]
Website: www.acgroup.global


GLOBENEWSWIRE (Distribution ID 9256055)

Manzil and Spectator Launch Strategic Partnership Advancing Tech-Enabled Home Care in Saudi Arabia, UAE, and Qatar

ABU DHABI, United Arab Emirates and SITTARD, The Netherlands , Oct. 10, 2024 (GLOBE NEWSWIRE) — Manzil Healthcare Services (“Manzil”), a leader in home health and disease management services in the Middle East, and Spectator Healthcare Technology (“Spectator”), the Dutch pioneer in integrated telehealth technology, today announce a strategic partnership bringing tech–enabled solutions to transform healthcare delivery in Saudi Arabia, UAE, and Qatar.

Manzil provides high quality medical services to a patient’s doorstep – from postnatal care to medical infusions to elder care – leveraging a 360+ professional network of nurses, physicians, and therapists, as well as innovative technology solutions.

The Spectator Telehealth Platform, in conjunction with the company’s white–labeled BiDiApp for mobile devices and Tele–Assistance Room for remote/rural areas, will offer Manzil’s patients a wide range of telehealth services and AI–enhanced tools, including the monitoring of vitals (e.g., heartbeat, oxygen levels, and blood pressure).

The partnership between Manzil and Spectator is centered around three key pillars: enhancing the quality of care, increasing accessibility to healthcare services, and reducing the overall costs. Furthermore, integrated and secure data systems will ensure patients receive coordinated care, whether at home, in hospitals, or in long–term care facilities.

Lead investor in Manzil, TVM Capital Healthcare, strengthens this collaboration with decades of experience in the Middle East improving healthcare quality, accessibility, and affordability through a focus on specialty care outside of traditional hospitals. Based in Dubai and Singapore, with offices in Riyadh and Ho Chi Minh City, the investor–operator has a proven track record of driving growth in emerging market healthcare businesses.

With increasing populations and heightened demand for high–quality, accessible healthcare, UAE, Qatar, and Saudi Arabia represent markets well–positioned to benefit from solutions that offer:

  • Localized healthcare delivery models tailored to the specific needs of the populations in these regions;
  • Reduced reliance on in–person hospital visits through remote monitoring and AI–based diagnostics; and,
  • Enhanced chronic care management for conditions like diabetes and heart disease, with real–time monitoring tools

These countries have also recently implemented government initiatives designed to modernize their healthcare systems and encourage investment from both the public and private sectors. For example, Saudi Arabia’s Vision 2030 and Health Sector Transformation Program prioritize improved access to quality care and digital solutions to improve the efficiency and effectiveness of the healthcare sector.

“Caring for patients in their home allows for faster recoveries and better outcomes while they stay close to those who mean the most to them. Spectator’s technology enhances our abilities to offer multidisciplinary care wherever the patient may be and strengthens our position as the leading in–home health provider in the region,” commented Mohamed Saadany, CEO of Manzil Healthcare Services.

“Our cutting–edge integrated and AI powered telehealth solutions, based on a sustainable business model, will support Manzil’s dedicated healthcare providers in the region, ensuring they can implement tech–enabled and customized care solutions,” said Dr. Frans Hermes, Founder and Managing Director of Spectator Healthcare Technology. “In addition to our existing projects and partners across four continents, we are excited to bring these benefits now to UAE, Qatar, and Saudi Arabia, supporting their visions of enhancing access to quality care.”

“This partnership between Manzil and Spectator creates a power solution for increasing access to affordable, quality care in the Middle East and we look forward to future expansion to other markets,” remarked Carl Stanifer, Operating Partner, Middle East and Southeast Asia, for TVM Capital Healthcare and Chairman of the Board for Manzil Healthcare Services.

For more information, visit ManzilHealth.com and Spectator–Healthcare.com.

For media inquiries, contact:

Holly Radel
[email protected]


GLOBENEWSWIRE (Distribution ID 1000996679)

Manzil و Spectator ﺗطﻠﻘﺎن ﺷراﻛﺔ اﺳﺗراﺗﯾﺟﯾﺔ ﻟﺗﻌزﯾز اﻟرﻋﺎﯾﺔ اﻟﻣﻧزﻟﯾﺔ اﻟﻣدﻋوﻣﺔ ﺑﺎﻟﺗﻛﻧوﻟوﺟﯾﺎ ﻓﻲ اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ واﻹﻣﺎرات اﻟﻌرﺑﯾﺔ اﻟﻣﺗﺣدة وﻗطر.

أبوظبي، الإمارات العربية المتحدة، وسيتارد، هولندا, Oct. 10, 2024 (GLOBE NEWSWIRE) — أعلنت اليوم شركة Manzil Healthcare Services، الرائدة في مجال الرعاية الصحية المنزلية وإدارة الأمراض في الشرق الأوسط، وشركة Spectator Healthcare Technology الهولندية، الرائدة في تكنولوجيا الرعاية الصحية عن بُعد، عن إطلاق شراكة استراتيجية تهدف إلى تطوير حلول مبتكرة ومدعومة بالتكنولوجيا لإحداث نقلة نوعية في تقديم الرعاية الصحية في المملكة العربية السعودية، الإمارات العربية المتحدة، وقطر.

تقدّم Manzil  خدمات طبية شاملة في المنازل، في جميع المراحل العمرية، بدءًا من رعاية ما بعد الولادة وصولاً إلى رعاية المسنين، شاملة كافة الخدمات الطبية. تعتمد الشركة على فريق محترف يضم أكثر من 360 طبيبًا، ممرضًا، ومعالجًا، إلى جانب تبني حلول تقنية مبتكرة لتقديم خدمات عالية الجودة.

ستقدم منصة Spectator Telehealth Platform  للرعاية الصحية عن بُعد، بالتعاون مع تطبيق BiDiApp، مجموعة من الخدمات الصحية المدعومة بالذكاء الاصطناعي لمراقبة المؤشرات الحيوية مثل ضربات القلب، مستويات الأكسجين، وضغط الدم، ومؤشرات آخرى، خاصة في المناطق الريفية والنائية لمرضى Manzil .

تركّز الشراكة بين Manzil  وSpectator  على ثلاثة أهداف رئيسية: تحسين جودة الرعاية، توسيع نطاق الوصول إلى الخدمات الصحية، وخفض التكاليف الإجمالية للرعاية الصحية. كما ستشمل الشراكة استخدام أنظمة بيانات متكاملة وآمنة لضمان تقديم رعاية منسقة سواء في المنازل أو في المستشفيات أو في مرافق الرعاية الصحية طويلة الأمد.

تأتي هذه الشراكة بدعم من TVM Capital Healthcare، المستثمر الرئيسي في Manzil، والذي يتمتع بخبرة طويلة في تحسين جودة الرعاية الصحية وزيادة إمكانية الوصول إليها في منطقة الشرق الأوسط، مع التركيز على الرعاية المتخصصة خارج المستشفيات التقليدية.

وﻓﻲ ظل ﺗزاﯾد ﻋدد اﻟﺳﻛﺎن وزﯾﺎدة اﻟطﻠب ﻋﻠﻰ اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ ﻋﺎﻟﯾﺔ اﻟﺟودة اﻟﺗﻲ ﯾﺳﮭل ﻟﻠﻣرﺿﻰ اﻟوﺻول إﻟﯾﮭﺎ، ﺗﻣُﺛل اﻹﻣﺎرات اﻟﻌرﺑﯾﺔ اﻟﻣﺗﺣدة وﻗطر واﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ أﺳواﻗﺎً ﻓﻲ وﺿﻊ ﻣﺗﻣﯾز ﻟﻼﺳﺗﻔﺎدة ﻣن اﻟﺣﻠول اﻟﺗﻲ ﺗﻘدم:

  • ﻧﻣﺎذج ﻟﺗﻘدﯾم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ ﻣﺻﻣﻣﺔ ﺧﺻﯾﺻﺎً ﻟﺗﻠﺑﯾﺔ اﻻﺣﺗﯾﺎﺟﺎت اﻟﻣﺣددة ﻟﻠﺳﻛﺎن ﻓﻲ ھذه اﻟﻣﻧﺎطﻖ.
  • ﺗﻘﻠﯾل اﻻﻋﺗﻣﺎد ﻋﻠﻰ اﻟذھﺎب ﻟﻠﻣﺳﺗﺷﻔﯾﺎت ﻣن ﺧﻼل اﻟﻣراﻗﺑﺔ ﻋن ﺑﻌُد واﻟﺗﺷﺧﯾص اﻟﻘﺎﺋم ﻋﻠﻰ اﻟذﻛﺎء اﻻﺻطﻧﺎﻋﻲ.
  • ﺗﺣﺳﯾن إدارة رﻋﺎﯾﺔ اﻟﺣﺎﻻت اﻟﻣزﻣﻧﺔ ﻣﺛل اﻟﺳﻛري وأﻣراض اﻟﻘﻠب، ﺑﺟﺎﻧب ﺗوﻓﯾر أدوات ﻣراﻗﺑﺔ ﻟﺣظﯾﺔ.

وﻗد ﻧﻔذت ھذه اﻟدول ﻓﻲ اﻵوﻧﺔ اﻷﺧﯾرة ﻣﺑﺎدرات ﺣﻛوﻣﯾﺔ ﺗﮭدف إﻟﻰ ﺗﺣدﯾث أﻧظﻣﺔ اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ وﺗﺷﺟﯾﻊ اﻻﺳﺗﺛﻣﺎر ﻣن اﻟﻘطﺎﻋﯾن اﻟﻌﺎم واﻟﺧﺎص. ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل، ﺗﻌطﻲ رؤﯾﺔ اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ 2030 وﺑرﻧﺎﻣﺞ ﺗﺣول اﻟﻘطﺎع اﻟﺻﺣﻲ اﻷوﻟوﯾﺔ ﻟﺗﺣﺳﯾن اﻟوﺻول إﻟﻰ اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ اﻟﻣﺗﻣﯾزة واﻟﺣﻠول اﻟرﻗﻣﯾﺔ ﻟﺗﺣﺳﯾن ﻛﻔﺎءة وﻓﻌﺎﻟﯾﺔ ﻗطﺎع اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ.

ﻣن ﺟﮭﺗﮫ صرّح محمد السعدني، الرئيس التنفيذي لشركة Manzil Healthcare Services  قائلاً: “تتيح لنا رعاية المرضى في منازلهم تقديم رعاية أسرع وأفضل، مع الحفاظ على راحتهم بجانب أحبائهم. شراكتنا مع Spectator  تعزز قدراتنا على تقديم رعاية متعددة التخصصات في أي مكان، مما يعزز مكانتنا كشركة رائدة في مجال الرعاية الصحية المنزلية في المنطقة.”

من جهته أيضاً، قال الدكتور هيرميس فرانس، المؤسس والمدير التنفيذي لشركة Spectator Healthcare Technology: “ ستدعم حلولنا المتكاملة والمتطورة المدعومة بالذكاء الاصطناعي مقدمي الرعاية الصحية المتخصصين في Manzil  لتقديم رعاية صحية مخصصة ومدعومة بالتكنولوجيا. ونحن متحمسون لتوسيع هذه الفوائد إلى السعودية، الإمارات، وقطر، بما يتماشى مع رؤى هذه الدول لتعزيز الوصول إلى الرعاية الصحية المتميزة.”

وأﺷﺎر كارل ستانفير ، اﻟﺷرﯾك اﻟﺗﺷﻐﯾﻠﻲ ﻓﻲ اﻟﺷرق اﻷوﺳط وﺟﻧوب ﺷرق آﺳﯾﺎ ﻟﺷرﻛﺔ Healthcare Capital TVM ورﺋﯾس ﻣﺟﻠس إدارة Services Healthcare :Manzil “ﺗوﻓر اﻟﺷراﻛﺔ ﺑﯾن Manzil وSpectator ﺣﻼً ﻗوﯾﺎً ﻟﺗﻌزﯾز اﻟﺣﺻول ﻋﻠﻰ رﻋﺎﯾﺔ ﺻﺣﯾﺔ ﻋﺎﻟﯾﺔ اﻟﺟودة ﻣﯾﺳورة اﻟﺗﻛﻠﻔﺔ ﻓﻲ اﻟﺷرق اﻷوﺳط، وﻧﺗطﻠﻊ إﻟﻰ اﻟﺗوﺳﻊ اﻟﻣﺳﺗﻘﺑﻠﻲ ﻓﻲ أﺳواق أﺧرى“.

.Spectator–Healthcare.comو  ManzilHealth.com زﯾﺎرة ﯾرﺟﻰ اﻟﻣﻌﻠوﻣﺎت، ﻣن ﻟﻠﻣزﯾد

ﻻﺳﺗﻔﺳﺎرات اﻟﺟﮭﺎت اﻹﻋﻼﻣﯾﺔ، ﯾرﺟﻰ اﻟﺗواﺻل ﻣﻊ:

هولي راديل
[email protected]


GLOBENEWSWIRE (Distribution ID 1000996678)

Policymakers should recognise #SelfCareIsHealthcare in campaign bid to address global health challenges

  • Self–care describes the role of individuals in preventing disease, promoting and maintaining their mental and physical health, and actively participating in their healthcare
  • A wealth of evidence demonstrates the significant value of self–care to individuals, health systems, society and the economy

  • Despite this, self–care is not universally viewed or understood as a healthcare intervention and there is unequal access to self–care interventions around the world

GENEVA, July 24, 2024 (GLOBE NEWSWIRE) — The Global Self–Care Federation (GSCF) is urgently calling upon policymakers and health leaders worldwide to embrace self–care as an essential component of healthcare, by ensuring it is fully integrated into national health systems and policies, as part of this year’s International Self–Care Day on July 24.

The concept of self–care was first recognised by the World Health Organization (WHO) in 1983. It describes the role of individuals in preventing disease, promoting and maintaining their mental and physical health, and actively participating in their healthcare. Examples of self–care practices include medicines, devices, diagnostics digital tools as well as healthy lifestyle choices.

As health systems worldwide continue to face a range of challenges – from increased demand on services, to inequity in access to healthcare – evidence shows that self–care can:

  • avert an estimated 3.9 million premature deaths each year, through physical activity alonei
  • save nearly $120 billion each year for global healthcare systems and, therefore, national economiesii
  • improve the autonomy and agency of disadvantaged groups, including women and girls, in managing their own healthiii
  • provide a legitimate tool in the pursuit of universal health coverageiv

Judy Stenmark, Director General of GSCF, said: “Right now, health systems around the world are struggling, long–term ill health is on the rise, health disparities are growing and the impact of COVID–19 is still being felt. Addressing these requires new approaches and strategies, including evidence–based self–care – to achieve sustainable health services fit for the future.

“Our ‘Self–care is healthcare’ campaign is all about fuelling the movement for self–care to be recognised as an integral part of healthcare. It aims to drive greater awareness and recognition of the potential of self–care to people and policymakers across the world. At GSCF, we firmly believe that everyone benefits when there is a greater choice of healthcare options and more accessible entries to care.”

Building on this year’s International Self–Care Day, GSCF is urging members and campaigners to rally behind the #SelfCareIs movement. This initiative aims to educate global audiences about the critical link between self–care and healthcare. It also encourages engagement with local policymakers and healthcare providers to call on them to put in place plans for the urgent integration of self–care into the healthcare delivery continuum.

To find out more and to get involved, please visit the campaign website: https://self–care–is–healthcare.org/.

Notes to editors

WHO definition of self–care
Self–care is the ability of individuals, families and communities to promote health, prevent disease, maintain health, and cope with illness and disability with or without the support of a health worker.

About The Global Self–Care Federation
The Global Self–Care Federation represents associations and manufacturers in the self–care industry, promoting sustainable and better global health outcomes for all. The Global Self–Care Federation is the go–to source of information for the self–care industry. We work closely with our members and relevant stakeholder groups to deliver better choice, better care and better value. By placing the benefits of self–care at the heart of what we do, promoting industry transparency, and supporting the regulated use of health data, we ensure that self–care continues to play its increasingly vital role in sustainable healthcare, worldwide. For more information please visit: www.selfcarefederation.org.

About International Self–Care Day
International Self–Care Day is held annually on July 24th (7/24), to highlight that the benefits of self–care are experienced 24 hours a day, seven days a week. International Self–Care Day raises awareness of the value of self–care and the benefit that effective self–care can bring to both individuals and healthcare systems as a vital foundation of health.

i https://www.who.int/news–room/fact–sheets/detail/self–care–health–interventions#:~:text=Self%2Dcare%20is%20the%20ability,a%20health%20or%20care%20worker.
ii https://www.selfcarefederation.org/ecosoc–report
iii https://www.nature.com/articles/s41591–024–02844–8#Sec19
iv https://www.who.int/health–topics/self–care#tab=tab_1

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b4ee215a–f0b4–4837–a280–90659dcf5aa5


GLOBENEWSWIRE (Distribution ID 1000982941)

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real–world setting for hemophilia B in Europe.

HEMGENIX® is the first one–time gene therapy approved in Europe for the treatment of adults with severe and moderately severe hemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1

Following European Commission approval, HEMGENIX® was the first ever therapy to be granted Direct Access in France2, thus enabling the first patients to be treated in Europe outside of the clinical program.

Though effective, current therapies can be time intensive and require regular treatment that can have a substantial impact on a patient’s daily life.3 HEMGENIX® offers a one–time treatment, allowing people living with hemophilia B to produce their own Factor IX, which can lower the risk of bleeding.4

“Only a few decades ago, gene therapy for hemophilia was a distant concept, which has now become reality. Accordingly, the first two patients treated with HEMGENIX® since receiving European approval is a major accomplishment and a testament to the joint commitment of the hemophilia B community, as well as the access and reimbursement authorities, in bringing innovative therapies to patients,” said Dr Lutz Bonacker SVP and General Manager, CSL Behring Commercial Operations Europe. “This milestone has been made possible by the innovative Direct Access scheme adopted in France, allowing patients to benefit from early access to pioneering treatments. We are encouraged to see increasing access to gene therapies in European countries and are fully committed to ensuring that access to potentially life–changing treatment continues.”

HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022. It has also been approved by Health Canada, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), Switzerland’s Swissmedic and Australia’s Therapeutic Goods Administration (TGA).

The multi–year clinical development of HEMGENIX® was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment.

About Hemophilia B

Hemophilia B is a life–threatening rare disease. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and joint damage. Current treatments for moderate to severe hemophilia B include life–long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood–clotting factor.  

About HEMGENIX®

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non–infectious viral vector, called an adeno–associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX–Padua) to the target cells in the liver, generating factor IX proteins that are 5x–8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

About the Pivotal HOPE–B Trial

The pivotal Phase III HOPE–B trial is an ongoing, multinational, open–label, single–arm study to evaluate the safety and efficacy of HEMGENIX®. Fifty–four adult hemophilia B patients classified as having moderately severe to severe hemophilia B and requiring prophylactic factor IX replacement therapy were enrolled in a prospective, six–month or longer observational period during which time they continued to use their current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR). After the six–month lead–in period, patients received a single intravenous administration of HEMGENIX® at the 2×10^13 gc/kg dose. Patients were not excluded from the trial based on pre–existing neutralizing antibodies (NAbs) to AAV5.

A total of 54 patients received a single dose of HEMGENIX® in the pivotal trial, with 52 patients completing at least three years of follow–up. The primary endpoint in the pivotal HOPE–B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six–month lead–in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady–state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.

No serious treatment–related adverse reactions were reported. One death resulting from urosepsis and cardiogenic shock in a 77–year–old patient at 65 weeks following dosing was considered unrelated to treatment by investigators and the company sponsor. A serious adverse event of hepatocellular carcinoma was determined to be unrelated to treatment with HEMGENIX® by independent molecular tumour characterization and vector integration analysis. No inhibitors to factor IX were reported. 

Long–term three–year data presented at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2024 continue to reinforce the potential long–lasting efficacy and safety of HEMGENIX® and the ongoing benefit of this treatment for people living with hemophilia B.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

Media Contacts
Stephanie Fuchs
Mobile: +49 151 584 388 60
Email: [email protected]

References

1 European Medicines Agency. First Gene therapy to treat haemophilia B. Available at: https://www.ema.europa.eu/en/news/first–gene–therapy–treat–haemophilia–b. [Accessed May 2024].
2 Republique Française. Légifrance: Article 62 of Law No. 2021–1754. Available at: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000048551003 [Accessed May 2024].
3 Leebeek, F & Miesbach, W. (2021) Gene therapy for haemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. Vol 138, Issue 11. pp923–931.
4 Coppens M et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE–B): 24–month post–hoc efficacy and safety data from a single–arm, multicentre, phase 3 trial. The Lancet Haematology 2024; 11(4):E265–E275.


GLOBENEWSWIRE (Distribution ID 1000969961)